THERAPEUTIC OR PROPHYLACTIC AGENT FOR MULTIPLE SCLEROSIS.

• 1. 含吲哚化合物的多发性硬化症治疗剂或预防剂 [P] . 中国专利： CN112118844A . 2020-12-22
• 2. 多发性硬化症的治疗剂或预防剂 [P] . 中国专利： CN105934245B . 2019.04.09
• 3. THERAPEUTIC OR PROPHYLACTIC AGENT FOR MULTIPLE SCLEROSIS. [P] . MX2016009932A . 2017-01-11

  机译： 多发性硬化症的治疗或预防剂。

• 4. Method for testing risk of multiple system atrophy, test kit, and therapeutic or prophylactic agent for multiple system atrophy [P] . 日本专利： JP6358962B2 . 2018-07-18

  机译： 测试多系统萎缩的风险的方法，试剂盒以及用于多系统萎缩的治疗剂或预防剂

• 5. Method for testing risk of multiple system atrophy, test kit, and therapeutic or prophylactic agent for multiple system atrophy [P] . 日本专利： JPWO2014123151A1 . 2017-02-02

  机译： 测试多系统萎缩的风险的方法，试剂盒以及用于多系统萎缩的治疗剂或预防剂

• 1. Galectin-3 prospects as a therapeutic agent for multiple sclerosis [J] . Laura Thomas, Laura Andrea Pasquini 中国神经再生研究（英文版） . 2019,第008期
• 2. Estrogens as potential therapeutic agents in multiple sclerosis. [J] . Niino M, Hirotani M, Fukazawa T, Central nervous system agents in medicinal chemistry . 2009,第2期
• 3. Statins as potential therapeutic agents in multiple sclerosis. [J] . Stuve O, Prodhomme T, Youssef S, Current neurology and neuroscience reports. . 2004,第3期
• 4. Therapeutic effect of anthracene-based anticancer agent ethonafide in an animal model of multiple sclerosis. [J] . Piao WH, Wong R, Bai XF, The Journal of Immunology: Official Journal of the American Association of Immunologists . 2007,第11期
• 5. Chimpanzee ad vector technology platform for prophylactic and therapeutic genetic vaccine applications [C] . Stefano Colloca Vaccine technology IV . 2012
• 6. Determining Cellular and Molecular Mechanisms of Multivalent Soluble Antigen Arrays that Contribute to Therapeutic Efficacy Against a Murine Model of Multiple Sclerosis. [D] . Hartwell, Brittany L. 2016
• 7. Difference in effect of single immunosuppressive agents (cyclophosphamide CCNU 5-FU) on peripheral blood immune cell parameters and central nervous system immunoglobulin synthesis rate in patients with multiple sclerosis. [O] . W W Shih, R W Baumhefner, W W Tourtellotte, 1983
• 8. Multiple functional therapeutic effects of TnP: A small stable synthetic peptide derived from fish venom in a mouse model of multiple sclerosis. [O] . Evilin Naname Komegae, Tais Aparecida Matozo Souza, Lidiane Zito Grund, 2017

• 1. Novel agents and new therapeutic approaches for treatment of multiple myeloma [J] . Roberto Ria ,Antonia Reale ,Angelo Vacca . 世界方法学杂志 . 2014,第2期
• 2. A prospective randomized study to define the role of low dose continuous prophylactic antibiotics and anti-adherence agents in altering the microbial colonization related to indwelling double‐J stents [J] . Kumar Madhavan ,Sanchit Rustagi ,Rahul Jena . 亚洲泌尿外科杂志(英文) . 2021,第3期
• 3. The Role of Prophylactic Antibiotic Use in Prevention of Endophthalmitis Following Intravitreal Injection of Anti-Vascular Endothelial Growth Factor Agents: A Meta-Analysis [J] . Sonia B. Dhoot ,Nancy Kunjukunju ,Nelson Sabates . 眼科学期刊（英文） . 2013,第2期
• 4. Which Patients Should be Administrated Prophylactic Antibacterial Agents? A Study of Bacteriuria or Funguria by Urine Culture Taken From the Renal Pelvis in Children with Ureteropelvic Junction Obstruction [J] . Gao-Yan Deng ,Li-Yu Zhang ,Zhong-Ming Li . 泌尿学期刊（英文） . 2011,第4期
• 5. 多发性硬化症(MS)患者慢性脑脊髓静脉供血不足(CCSVI)的血管内介入治疗-美国介入放射学会(SIR)起草并由加拿大介入放射学会认可的申明 [C] . 周政 . 2010年全国介入放射学新技术研讨会 . 2010
• 6. 来那度胺促进巨噬细胞M2型极化治疗多发性硬化症的分子机制研究 [A] . 王静 . 2016